Weight gain during olanzapine treatment for psychotic depression: effects of dose and age.

International Clinical Psychopharmacology
Eric SmithSTOP-PD Collaborative Study Group

Abstract

Weight gain has often been associated with olanzapine treatment, yet little is known about the influence of patient age or cumulative dose on olanzapine-associated weight gain. The first 118 participants in the National Institutes of Mental Health Study of the Pharmacotherapy of Psychotic Depression randomized clinical trial (ClinicalTrials.gov Registration NCT00056472) completing at least 4 weeks of treatment with olanzapine were analyzed to determine the relationship between weight gain, age, and cumulative olanzapine dose. Younger (age 18-59 years) and older (age 60+ years) participants received open-label olanzapine and either sertraline or placebo for up to 12 weeks. Linear mixed effect regression modeling was used to determine the effects of age and cumulative olanzapine dose on weight gain, controlling for potential confounders. Age was observed to have a significant negative association with weight gain (P=0.01), even after controlling for differences in cumulative dose and baseline body mass index. Each 10-year increase in age was associated with a decrease in mean weight gain over 12 weeks of approximately 0.6 kg (95% confidence interval: 0.14-1.05 kg). Cumulative olanzapine dose was also significantly associated with...Continue Reading

Associated Clinical Trials

References

Jul 1, 1987·Acta Psychiatrica Scandinavica·S C Newman, R C Bland
Dec 10, 1999·The Journal of Clinical Psychiatry·D N OsserR L Dufresne
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Jan 30, 2004·Diabetes Care·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Jul 3, 2004·Journal of Clinical Psychopharmacology·Anthony J RothschildGary D Tollefson
Jan 12, 2005·The Journal of Clinical Psychiatry·John HennenRoss J Baldessarini
Dec 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Robert B ZipurskyJeffrey A Lieberman
May 17, 2006·Journal of Clinical Psychopharmacology·Ilya LipkovichThomas Hardy
Oct 3, 2006·The American Journal of Psychiatry·Wayne S Fenton, Mark R Chavez
Oct 19, 2006·Biological Psychiatry·Barnett S MeyersUNKNOWN STOP-PD Study Group

❮ Previous
Next ❯

Citations

Nov 23, 2011·Clinical Neuropharmacology·Sandra SchönfelderMathias Zink
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Jul 17, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Tamás TreuerSusanna Holt
May 26, 2018·International Psychogeriatrics·Emme ChackoRinki Murphy
Sep 5, 2008·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here